GlassScriptPhysician profile
Alexander David Woods
NPI 1306586003
$7,732.12
in general payments reported to CMS, 2019-2025
19 companies · $4,907 in 2025
The $4,907 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,304 · 2024: $1,522 · 2025: $4,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,510 · Travel and Lodging: $1,842 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,510.38 |
| Travel and Lodging | $1,841.77 |
| Education | $379.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,379.04 | 2023-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,297.90 | 2023-2025 | Tremfya |
| Genzyme Corporation | $827.17 | 2023-2025 | |
| Lilly USA, LLC | $629.79 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Mimedx Group, INC. | $279.64 | 2024 | |
| Integra Lifesciences Corporation | $273.96 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Sun Pharmaceutical Industries INC. | $254.50 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $168.87 | 2024-2025 | Libtayo, Dupixent |
| Incyte Corporation | $125.89 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.30 | 2023-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $64.47 | 2025 | |
| Galderma Laboratories, L.P. | $50.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.38 | 2025 | |
| Merz Pharmaceuticals, LLC | $43.25 | 2024 | Xeomin |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $38.67 | 2025 | |
| Ucb, INC. | $34.14 | 2025 | Bimzelx |
| Tactile Systems Technology INC | $28.79 | 2025 | Flexitouch Plus, Nimbl |
| Biofrontera INC. | $18.37 | 2024 | Ameluz, Rhodoled Xl, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.